Skip to main content
. 2014 Nov 17;9(11):e111652. doi: 10.1371/journal.pone.0111652

Figure 1. Consort diagram and clinical outcome of enrolled patients.

Figure 1

Patients were taken off of conventional therapies from two weeks prior to and 30 days after treatment with 131I-CLR1404. After treatment with 131I-CLR1404, patients underwent nuclear medicine procedures for 14 days and were followed for safety for 42 days.